Evaluating Glucagon-like Peptide-1 (GLP-1) Receptor Agonists for Possible Risk of NAION Side Effects
(Posted by Tom Lamb at Drug Injury Watch)
The FDA has been investigating "potential signals" of non-arteritic anterior ischemic optic neuropathy (NAION) with the glucagon-like peptide-1 (GLP-1) receptor agonist class of drugs. For example, NAION with Mounjaro, Zepbound, Wegovy, Rybelsus, and Ozempic.
From "October - December 2024 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)", here is a full list of the glucagon-like peptide-1 (GLP-1) receptor agonists, or GLP-1 RAs, that are being evaluated:
Adlyxin (lixisenatide) injection
Bydureon (exenatide) for extended-release injectable suspension
Bydureon BCise (exenatide extended-release) injectable suspension
Byetta (exenatide) injection
Mounjaro (tirzepatide) injection
Ozempic (semaglutide) injection
Rybelsus (semaglutide) tablets
Saxenda (liraglutide) injection
Soliqua 100/33 (insulin glargine and lixisenatide) injection
Trulicity (dulaglutide) injection
Victoza (liraglutide) injection
Wegovy (semaglutide) injection
Xultophy 100/3.6 (insulin degludec and liraglutide) injection
Zepbound (tirzepatide) injection
__________________________________________________________________
Mounjaro / Zepbound
Free Case Evaluation
Strictly Confidential, No Obligation.
__________________________________________________________________
In early June 2025, the European Medicines Agency (EMA) confirmed the link between the semaglutide-containing drugs Wegovy, Rybelsus, and Ozempic and NAION (non-arteritic anterior ischemic optic neuropathy). This drug regulator went on to say a NAION warning would be added to the drug labels for Wegovy, Rybelsus, and Ozempic in Europe.
__________________________________________________________________
Ozempic / Wegovy / Rybelsus
Free Case Evaluation
Strictly Confidential, No Obligation.
__________________________________________________________________
We have posted several articles on Drug Injury Watch during the past year about NAION linked to Ozempic, Rybelsus, and Wegovy:
- March 2025 Medical Article About Blindness or Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients (3/31/25)
- Ozempic Vision Problems From Semaglutide Apply to Wegovy and Rybelsus, Also (2/21/25)
- Novo Nordisk Semaglutide Drug Ozempic Linked to Vision Loss, Doubling the Risk: December 2024 Update (12/18/24)
- Wegovy, Rybelsus, and Ozempic Eye Side Effects: Semaglutide Linked to NAION (7/5/24)
As seen in those articles, the link between the semaglutide-containing drugs and NAION is fairly well-established by this point in time.
This is our first consideration of NAION with Mounjaro, Zepbound, and other GLP-1 RAs besides Wegovy, Rybelsus, and Ozempic.
We will monitor the FDA, the EMA, and other drug regulators, as well as the relevant medical literature, for developments concerning a possible association of NAION with the tirzepatide-containing drugs Mounjaro and Zepbound as well as those various drugs with the active ingredients dulaglutide, exenatide, liraglutide, and lixisenatide (see the above list for brand-name information).
If you have developed NAION with Mounjaro, Zepbound, or other GLP-1 RAs -- including Wegovy, Rybelsus, and Ozempic -- there might be a drug injury lawsuit against the responsible pharmaceutical company. Please don't hesitate to contact us if you are interested in such a case.
DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects
Drug Injury Case Evaluation - Free. Confidential. No Obligation.